Role of HIS score in predicting the prognosis of anti-melanoma differentiation associated gene 5 antibody-positive dermatomyositis patients with interstitial lung disease
10.3760/cma.j.cn141217-20210830-00350
- VernacularTitle:HIS评分在抗黑色素瘤分化相关基因5抗体阳性皮肌炎合并间质性肺疾病预后评估中的应用价值
- Author:
Jiajia WANG
1
;
Lei WANG
;
Lingxiao XU
;
Chengyin LYU
;
Yujing ZHU
;
Fang WANG
;
Miaojia ZHANG
;
Wenfeng TAN
Author Information
1. 南京医科大学第一附属医院（江苏省人民医院）风湿免疫科，南京 210019
- Keywords:
Lung diseases, interstitial;
Prognosis;
Idiopathic inflammatory myopathy;
Anti-melanoma differentiation associated gene 5;
HIS score
- From:
Chinese Journal of Rheumatology
2022;26(4):224-230
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the role of HIS (hyperinflammatory syndrome) score in predicting the prognosis of anti-melanoma differentiation associated gene 5(MDA5) antibody-positive dermatomyositis (DM) patients with interstitial lung disease (ILD).Methods:A total of 43 patients with anti-MDA5 antibody-positive dermatomyositis and 228 connective tissue disease (CTD) patients with ILD hospitalized in the First Affiliated Hospital of Nanjing Medical University from January 2018 to April 2021 were enrolled into this study. All patients were complicated with ILD and their HIS score were assessed. Non-parametric Mann-Whitney U test, Chi-squared test, Fisher exact probability and receiver operating characteristic (ROC) curve were used for data analysis. Results:The HIS score of 43 patients with anti-MDA5 antibody-positive dermat-omyositis were collected. Among 228 CTD-ILD patients in the control groups, the primary disease consisted of 33(14.5%) anti-synthetase antibody syndrome (ASS), 44(19.3%) rheumatoid arthritis (RA), 65(28.5%) Sj?gren's syndromes (SS), 43 (18.9%) systemic sclerosis (SSc) and 43 (18.9%) systemic lupus erythematosus(SLE). The HIS score of anti-MDA5-positive DM-ILD patients [2(1, 3)] was higher than those in ASS patients [1(0, 2), Z=-2.06, P<0.05] and significantly higher than those in RA-ILD [1(0, 2), Z=-2.87, P<0.01], SS-ILD [0(0,1), Z=-5.78, P<0.01], SSC-ILD [1(0, 1), Z=-3.84, P<0.01] and SLE-ILD [1(0, 2), Z=-3.81, P<0.01]. Comparing HIS score of anti-MDA5-positive DM-ILD patients, the 3-months mortality rate in the low, medium and high groups was 0(0/15), 38.1%(8/21) and 85.7%(6/7). The area under ROC curve (95% CI) was 0.857[(0.747, 0.967), P<0.001] for HIS score in predicting 3-months mortality probability of anti-MDA5-positive DM-ILD. Conclusion:HIS score of anti-MDA5-positive DM-ILD is higher than that in CTD-ILD patients and the baseline level is related to the 3-months mortality rate.
